Ennov’s regulatory and quality offers have registered excellent results, positioning the company as one of the world’s leaders. The orders should enable another year of profitable growth. Ennov has greatly expanded its sales internationally over the past four years, particularly in North America and Europe. The company has also scaled up its global solutions for leading life science companies like Boehringer Ingelheim, Johnson & Johnson, and Viatris.

This growth confirms the relevance of Ennov’s product strategy, which is to offer the only unified platform in the market to date, with a unique data repository, seamless user experience, unified technology and configurations, and more.

Sales of the Ennov platform in SaaS have increased significantly and now represent a clear majority of sales, confirming the validity of the company’s cloud strategy. The new version of Ennov, Ennov V10, scheduled for release in Q2 2023, will introduce major innovations, including native AI capabilities, particularly NLP, and integration of the entire Ennov Clinical suite into the platform, including EDC and RTSM.

Ennov’s recent major references confirm the company’s commercial momentum, with German pharmaceutical group Stada choosing Ennov for its RIM, IDMP, regulatory document management, and eCTD submission solutions. The prestigious Institute for Cancer Research in London has also adopted Ennov to manage its clinical trials (Electronic Data Capture, electronic Trial Master File, and Clinical Trial Management System) and pharmacovigilance.

“Our regulatory and quality offers have registered excellent results and positioned us as one of the world’s leaders in the sector. The orders enable us to consider another year of profitable growth. We will accelerate our investments in internationalizing the company, human capital, and R&D in 2023.”

Olivier Pâris, CEO of Ennov

About Ennov:

Ennov provides the most comprehensive and flexible software suite for regulated content management in the life sciences industry. From large pharmaceutical companies to emerging biotechs, we are proud to serve over 300 companies in the sector worldwide. We develop innovative, powerful, and easy-to-use software for managing regulated content, data, and processes. Our solutions support the entire R&D continuum of life sciences, including clinical, regulatory, quality, pharmacovigilance, and commercial aspects.